Safety of greenlight photoselective vaporisation of prostate in lower urinary tract symptoms due to benign prostatic hyperplasia in patients using anticoagulants due to cardiovascular comorbidities

Basit Öğe Kaydı
dc.authorid0000-0001-5337-5226en_US
dc.contributor.authorCakiroglu, Basri
dc.contributor.authorSinanoglu, Orhun
dc.contributor.authorDogan, Akif Nuri
dc.date.accessioned2024-07-12T21:45:08Z
dc.date.available2024-07-12T21:45:08Z
dc.date.issued2015en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractLasers have been used in the management of benign prostatic hyperplasia for the last two decades. To be comparable, they should reduce or avoid the immediate and long-term complications of transurethral resection of the prostate (TURP) or open prostatectomy (OP), especially bleeding and need for blood transfusion. Although Holmium laser treatment of the prostate was compared frequently in terms of cardiovascular safety with TURP or OP, photoselective vaporisation of the prostate (PVP) was not largely evaluated. In this article we analyzed the current literature to see if there is convincing data to support the observation of some authors that use of PVP is associated with increased safety in patients on anticoagulants with cardiovascular comorbidities. With this purpose a Medline search between January 2004 to March 2013 was performed using evidence obtained from randomised trials, well-designed controlled studies without randomisation, individual cohort studies, individual case control studies and case reports Results: In the last 10 years, several case-control and cohort studies have demonstrated the efficacy of PVP as well as its safety in patients with cardiovascular comorbidities using anticoagulants. The results confirmed the overall lower peri-operative and postoperative morbidity of PVP, whereas the efficacy was comparable to TURP in the short term, despite a higher reoperation rate. Conclusion: Although it is still developing, PVP with KTP or LBO seems to be a promising alternative to both TURP and OP in terms of cardiovascular safety and in patients using anticoagulants.en_US
dc.identifier.doi10.4081/aiua.2015.2.141
dc.identifier.endpage143en_US
dc.identifier.issn1124-3562
dc.identifier.issn2282-4197
dc.identifier.issue2en_US
dc.identifier.pmid26150031en_US
dc.identifier.scopus2-s2.0-84947300415en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://dx.doi.org/10.4081/aiua.2015.2.141
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7799
dc.identifier.volume87en_US
dc.identifier.wosWOS:000440260400005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPAGEPRESS PUBLen_US
dc.relation.ispartofARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY00326
dc.subjectAnticoagulant therapyen_US
dc.subjectBenign prostate hyperplasiaen_US
dc.subjectCardiovascular comorbiditiesen_US
dc.subjectPhotoselective prostate vaporizationen_US
dc.titleSafety of greenlight photoselective vaporisation of prostate in lower urinary tract symptoms due to benign prostatic hyperplasia in patients using anticoagulants due to cardiovascular comorbiditiesen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu